Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab
Takashi Matsumura, Kenji Tsuchihashi, Takeo Yamamoto, Fumiaki Jinnouchi, Wataru Kusano, Yota Kusumoto, Kohei Arimizu, Hirofumi Ohmura, Yuki Kuma, Shohei Moriyama, Kyoko Yamaguchi, Mamoru Ito, Taichi Isobe, Hiroshi Ariyama, Yoshinao Oda, Koichi Akashi, Eishi Baba
著者情報
キーワード: Lymph proliferative disorders, EBV, Pembrolizumab, Immune checkpoint inhibitor
ジャーナル オープンアクセス 早期公開

論文ID: 3743-24

この記事には本公開記事があります。
The final version of this article is now available: Vol. 64 (2025), No. 11 pp. 1728-1732
詳細
PDFをダウンロード (837K)
メタデータをダウンロード RIS形式

(EndNote、Reference Manager、ProCite、RefWorksとの互換性あり)

BIB TEX形式

(BibDesk、LaTeXとの互換性あり)

テキスト
メタデータのダウンロード方法
発行機関連絡先
抄録

A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood. The patient was diagnosed with other iatrogenic immunodeficiency-associated lymph proliferative disorders (OIIA-LPDs) related to EBV activation induced by pembrolizumab. Rituximab was administered, resulting in the improvement of the OIIA-LPD. The emergence of an OIIA-LPD merits close attention in patients receiving immune checkpoint inhibitors.

著者関連情報
© 2024 by The Japanese Society of Internal Medicine

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
お気に入り & アラート

閲覧履歴
前身誌

Japanese Journal of Medicine

このページを共有する
feedback
 Top